Boston Scientific BSX Loss Contingency Accrual
Loss Contingency Accrual at other companies
Other financials
Where this comes from
Reported directly by Boston Scientific in its filing.
Tagged under the XBRL concept us-gaap:LossContingencyAccrualAtCarryingValue.
The source filing: Boston Scientific’s 10-Q, filed May 1, 2026.
- Filed
- May 1, 2026, 6:25 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0000885725-26-000033
Our accrual for legal matters that are probable and estimable was $229 million as of March 31, 2026 and $242 million as of December 31, 2025 and includes certain estimated costs of settlement, damages and defense primarily related to product liability cases or claims and matters assumed from acquired companies. We record certain legal charges, credits and costs of defense, which we consider to be unusual or infrequent and significant as Litigation-related net charges (credits) within our accompanying unaudited consolidated financial statements. We did not record any litigation-related net charges (credits) during the first quarter of 2026 or 2025. All other legal charges, credits and costs are recorded within Selling, general and administrative expenses within our accompanying unaudited consolidated statements of operations.
ITEM 1. CONSOLIDATED FINANCIAL STATEMENTS
FAQ
- What is Boston Scientific's loss contingency accrual?
- Boston Scientific (BSX) reported loss contingency accrual of $229M in Q1 2026.
- How has Boston Scientific's loss contingency accrual changed year-over-year?
- Boston Scientific's loss contingency accrual decreased by 27.5% year-over-year, from $316M to $229M.
- What is the long-term trend for Boston Scientific's loss contingency accrual?
- Over 5 years (2020 to 2025), Boston Scientific's loss contingency accrual has grown at a -15.7% compound annual growth rate (CAGR), from $569M to $242M.
Ask your AI about Boston Scientific's loss contingency accrual.
Connect your AI assistant and compare it to peers, right in your chat.
